Aura Biosciences Earnings Call Transcripts
Fiscal Year 2026
-
A novel virus-like drug conjugate platform is advancing in phase III for early choroidal melanoma, with additional studies in ocular and bladder cancers. The addressable market could reach 66,000 patients, and key data readouts are expected this year and in Q4 2027.
-
Strong progress in ocular oncology and bladder cancer programs, with phase III ocular melanoma trial on track for top-line data in Q4 2027 and mid-year data expected for bladder cancer. Market opportunities are expanding with ultra-orphan pricing and new indications, while safety and vision preservation remain key differentiators.
Fiscal Year 2025
-
A novel drug platform is advancing in late-stage trials for early choroidal melanoma and bladder cancer, with a strong safety profile and unique frontline positioning. Key milestones include phase III enrollment completion in 2026 and multiple proof-of-concept readouts in 2026.
-
A novel virus-like drug conjugate platform is advancing through late-stage trials in ocular and bladder cancers, targeting high unmet needs with strong early efficacy and safety data. Upcoming milestones include phase 3 enrollment completion and data readouts, with cash runway into 2027.
-
Late-stage clinical programs are advancing in ocular melanoma and bladder cancer, with strong efficacy, safety, and immune activation data supporting further development. Key data readouts are expected between late 2026 and early 2027, and rare disease pricing strategies are being pursued.
-
The VDC platform enables dual-selective, tumor-agnostic therapy with strong early data in ocular and bladder cancers. Phase 3 trials are underway globally, with rapid uptake expected in ocular oncology and expansion into other solid tumors considered. Recent fundraising extends operational runway into 2027.
-
A novel virus-like drug conjugate platform is advancing in phase III for uveal melanoma, showing strong efficacy and safety, with expansion into bladder cancer and other solid tumors. Key data readouts are expected within six months, and the company is fully funded through 2026.
-
Bel-sar's dual mechanism offers a novel, well-tolerated approach for NMIBC, showing strong early efficacy and immune activation. The updated phase 1B2 trial will optimize dosing and expand patient cohorts, with potential to disrupt current standards and reduce healthcare burden.
-
A novel virus-like drug conjugate platform is showing promise in early-stage ocular melanoma, achieving high tumor control and vision preservation, with a Phase III trial underway. The approach is expanding into bladder cancer, aiming for a paradigm shift in front-line therapy.
-
Advancing virus-like drug conjugates in ocular oncology and bladder cancer, with late-stage trials showing strong efficacy and organ preservation. Regulatory milestones achieved, with new data and study designs to be presented soon. Focus remains on early, local treatment to shift paradigms in cancer care.
Fiscal Year 2024
-
Bel-sar, a virus-like drug conjugate, shows strong efficacy in early-stage ocular melanoma with 80% local cure and 90% vision preservation, and promising results in bladder cancer. Phase 3 ocular study is global, with BLA submission targeted for 2026 and approval in 2027.
-
Phase I data for AU-011 in NMIBC show strong safety and efficacy, with high complete response rates and robust immune activation in both target and non-target lesions. The therapy is well-suited for office-based administration, addresses a large unmet need, and is advancing to expanded dosing and phase II trials.
-
Final phase II data for bel-sar in choroidal melanoma show 80% tumor control and 90% vision preservation at 12 months, with a strong safety profile. The ongoing global phase III COMPASS trial targets early-stage, high-risk tumors and could shift treatment paradigms toward earlier, vision-sparing intervention.
-
A novel virus-like drug conjugate platform is advancing through late-stage trials in ocular and urologic oncology, with strong interim data showing high efficacy and safety. Key data readouts are expected in September and October, and the company is well-funded through 2026.
-
A precision therapy platform enables direct tumor cell killing and immune activation, with strong phase II data in ocular oncology and promising early results in bladder cancer. Key milestones include a phase II data readout in September and further NMIBC data mid-year.